Headquarters building of Samsung Biologics. (Photo courtesy of Samsung Biologics)
Concerns over weakening order competitiveness are growing as Samsung Biologics’ new contract manufacturing organization (CMO) orders remain at just 1 contract this year. While stable order expansion was expected as order competitiveness was strengthened by the spin-off last year, stability risks are being highlighted to global clients due to the prolonged labor-man…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.